Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

Topic: Hoffmann-La Roche

    Note: these results are not from the primary (high quality) database.

Ads by Google

In the News (Mon 7 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

Hoffmann-La Roche - Wikipedia, the free encyclopedia In 1999, Roche pleaded guilty in the United States and paid a $500 million fine, then the largest fine ever secured in the U.S. The European Commission fined Roche 462 million euros for the same infraction in 2001, also a record fine at the time. Roche Holding AG is listed in on the SWX Swiss Exchange, ticker ROC.S. Its revenues during fiscal year 2002 were $9400 million, ranking 13th amongst the pharmaceutical companies of the world. Roche was fined accordingly, but unfortunately a bungle on the part of the EEC allowed the company to discover that it was Adams who had blown the whistle. en.wikipedia.org /wiki/Hoffmann-La_Roche   (619 words)

HOFFMANN-LA ROCHE v. Promega Roche responds to the district court’s analysis of this issue by arguing that the inventors and Dr. Kunkel simply differed over how to interpret the results of the experiments involving the prior art and claimed enzymes, and that a dispute of that sort cannot give rise to a finding of inequitable conduct.   Roche’s claim that another experiment measured a specific activity of approximately 390,000 units/mg also fails for similar reasons, because there is no proof that that experiment was performed under conditions equivalent to Example VI with a per milligram specific activity value approaching 250,000 “units,” as that term is defined in Example VI. Roche next suggests that the use of the past tense in Example VI is not really a misrepresentation since all of the steps in that procedure were purportedly part of two procedures that Roche did perform, Prep 3 and Prep 4. www.ll.georgetown.edu /federal/judicial/fed/opinions/00opinions/00-1372.html   (12217 words)

FDA Warning Letter, Hoffmann-La Roche, Inc. (Xeloda® (capecitabine) Tablets) Roche should immediately cease the distribution of these and other similar promotional materials for Xeloda that contain the same or similar claims or presentations. Roche should submit a written response to DDMAC on or before January 24, 2002, describing its intent and plans to comply with the above. In its letter to DDMAC, Roche should include the date on which these and other similarly violative materials were discontinued. www.pharmcast.com /WarningLetters/Yr2002/Jan2002/Hoffmann0102.htm   (461 words)

(BW) Hoffmann-La Roche, Gilead Sciences Announce Collaboration To Co-promote Potential Hepatitis C Treatment In The U.S. If this indication is approved, as part of the agreement, Roche will pay Gilead a percentage of overall product net sales for the hepatitis C indication in each of the three years of the collaboration. Roche is currently marketing Roferon-A in the United States for the treatment of several types of cancer and is awaiting marketing clearance for the treatment of chronic hepatitis C infection. Recognized for excellence in both biotechnology and traditional chemistry, Roche is also widely known for its current efforts in the research, development and commercialization of polymerase chain reaction (PCR), a revolutionary advance in diagnostics and other fields, including biomedical research, forensics and environmental testing. www.aegis.com /news/bw/1996/bw960924.html   (947 words)

Hoffmann-La Roche v. Invamed Roche, on behalf of Syntex, timely gave each defendant actual notice of the Syntex Patents and from that date has sought from each information that would assist Roche and Syntex in confirming whether each defendant’s synthesis of ticlopidine hydrochloride is within the lawful scope of one or more claims of the Syntex Patents. Roche and Syntex contend that Johnson, who made the initial contact and primarily conducted the negotiations, was acting in his capacity as a Vice-President of Roche and not as Roche’s counsel. Roche and Syntex then filed suit, in the United States District Court for the District of New Jersey, against Torpharm and other generic drug manufacturers that had filed applications. www.ll.georgetown.edu /Federal/judicial/fed/opinions/99opinions/99-1466.html   (2645 words)

Hoffmann-La Roche Limited The firm was founded in 1896 in Basel, Switzerland, by Fritz Hoffmann, who together with his wife, Adele La Roche, gave the company its name. Hoffmann-La Roche Limited will consider on an individual basis accommodation applicants interested in a specialty residency in one of these areas. This is the essence of the Roche culture found in operations on all continents and serving to meet a total "international commitment to health". www.utoronto.ca /pharmacy/indusphm/roche.htm   (511 words)

Millennium Pharmaceuticals, Inc. and Hoffmann-La Roche Achieve Research Milestone in Obesity F. Hoffmann-La Roche Ltd., with headquarters in Basel, Switzerland, and Hoffmann-La Roche Inc. with headquarters in Nutley, New Jersey, are members of The Roche Group, a world leader in research-based health care with activities in prescription pharmaceuticals, diagnostics, vitamins, fragrances and flavors and orthopedics. Roche will now move forward with high throughput screening, the next phase of the drug discovery process, to identify small molecules that act on the protein encoded by this gene, a key regulator of body weight. Roche has a long tradition of innovative breakthroughs in drug development and is a pioneer in medical applications of genetic engineering. www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-21-1998/0000636036&EDATE=   (632 words)

Hoffmann-La Roche Inc. Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals and diagnostics. "The Phelophepa Train is just one way in which we are demonstrating our responsibility to help patients who don't have access to quality medical care," said George Abercrombie, president and CEO of Hoffmann-La Roche Inc., the company's U.S. prescription pharmaceuticals division. Roche, the main external sponsor of the train in 2004, has supported the train since its inception in 1994. www.commondreams.org /cgi-bin/print.cgi?file=/news2004/1202-05.htm   (823 words)

635. Canthaxanthin (WHO Food Additives Series 22) Special studies on reproduction A three-generation study using 0 or 1000 ppm canthaxanthin in the diet revealed no adverse effects in any generation (Hoffmann-La Roche, 1966). Mortality and tumour incidence were not increased (Hoffmann-La Roche, 1966). The mean concentrations in other tissues were: liver, 0.08 µg/g; skin and spleen, 0.04 µg/g; and serum, 0.024 µg/ml (Hoffmann-La Roche, 1986). www.inchem.org /documents/jecfa/jecmono/v22je09.htm   (2577 words)

F. Hoffmann-La Roche and Sangamo BioSciences Sign Collaborative Research Agreement Roche discovers, develops and markets prescription drugs in key therapeutic areas such as diseases of the nervous system, virology, infectious diseases, oncology, cardiovascular diseases, inflammatory and autoimmune diseases, dermatology, metabolic disorders and respiratory diseases. Roche, headquartered in Basel, Switzerland, is a world leader in research-based healthcare with principal business in pharmaceuticals, diagnostics, vitamins, and fragrances and flavors. "We are extremely pleased to be working with Roche and to obtain access to their expertise in transgenic animal model systems for the application of Sangamo's Universal GeneTools," said Edward Lanphier, President and Chief Executive Officer. www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-02-1999/0000954143&EDATE=   (436 words)

F. Hoffmann-La Roche Ltd: First Quarter Exceeds Expectations: 15% Rise in Sales Results in Further Market Share Gains; Avastin Successfully Launched in United States Roche continues to hold a majority stake in Genentech, and its successful relationship with the US biotechnology company will remain unchanged. Roche Diagnostics strengthened its leading position in the Asia-Pacific region and Japan, for example, by expanding its partnership with Asian blood banks. Roche Diagnostics continued to grow significantly faster than the market in the first quarter of 2004. www.primezone.com /newsroom/news_releases.mhtml?d=56190   (3157 words)

Gilead -- Hoffmann-La Roche Submits New Drug Application to Market New Flu Pill Hoffmann-La Roche, Ltd. is a leading research-intensive pharmaceutical company that discovers, develops, manufactures and markets numerous important prescription drugs that improve, prolong and save the lives of patients with serious illnesses. NUTLEY, NJ, April 29, 1999 - F.Hoffmann-La Roche, Ltd. and Gilead Sciences, Inc. (NASDAQ:GILD), announced today that Roche has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for approval to market the only neuraminidase inhibitor in pill form, GS4104, for the treatment of influenza. Roche also plans to submit similar applications to regulatory authorities worldwide, starting with the European Union, Canada and Switzerland in the coming days. www.gilead.com /wt/sec/pr_933136352   (583 words)

Largest-Ever AIDS Study Finds Three Drug AIDS Cocktail Better Than Two Roche Laboratories Inc. is the marketing and sales subsidiary of Hoffmann-La Roche Inc., a leading research-intensive pharmaceutical company. These data, which come from an international clinical endpoint study, Hoffmann-La Roche Inc. trial SV 14604, demonstrate that three-drug therapy with a protease inhibitor is clinically superior to the standard two-drug regimen. Roche Laboratories markets more than 35 medications in major therapeutic areas including AIDS, oncology, transplantation, infectious diseases, cardiovascular diseases and dermatology. www.pslgroup.com /dg/2d06a.htm   (412 words)

NetSci: The Biotech YellowPages - Hoffmann-La Roche Roche is a leading healthcare company with a uniquely broad spectrum of innovative solutions. The integrated healthcare approach is increasingly offering ways of identifying and targeting diseases early, when their damaging effects can still be prevented. Our products and services address prevention, diagnosis and treatment of diseases, thus enhancing well-being and quality of life. www.netsci.org /Resources/Biotech/Yellowpages/H/roche.html   (66 words)

Hoffmann-La Roche Fact Sheet - Rx&D Hoffmann-La Roche Limited, also known as Roche, is a company that has built its success on innovation. Roche concentrates its efforts in seven core therapeutic areas and is known for its expertise in hospital markets. Roche operations in Canada are centered in Toronto (pharmaceuticals) and Montreal (diagnostics). www.canadapharma.org /Members/HoffmannLR_e.htm   (197 words)

PrimeZone Media Network Roche's recently launched combination hepatitis C therapy, Pegasys and Copegus, continues to be extremely successful, gaining market share in all major markets. Roche's new HIV fusion inhibitor, Fuzeon, is now available in 12 countries, and further major markets will be launching in the coming months. Roche is working closely with the FDA to address the agency's concerns about Disetronic's production processes and documentation and has taken steps to resolve these issues. www.primezone.com /pages/news_releases.mhtml?d=46582   (2729 words)

FDA Warning Letter, Hoffmann-La Roche Inc. (Xeloda® (capecitabine) Tablets) In addition, Roche representatives were observed disseminating the Sales Aid in the promotional exhibit area of the Twenty-Fifth Annual San Antonio Breast Cancer Symposium, held in San Antonio, Texas on December 11-14, 2002. As the Agency clearly informed Roche in the approval letter for Xeloda discussed above, promotional material that selectively presents surrogate endpoints such as response rate, and fails to provide information on the endpoint of survival, is false or misleading. Roche distributes the video to healthcare professionals, who in turn provide it to patients. www.pharmcast.com /WarningLetters/Yr2003/June2003/Roche0603.htm   (2943 words)

Second Middle East Oncology Meeting hosted in Dubai Hoffmann La-Roche Hoffmann-La Roche Ltd., one of the world's leading healthcare companies, hosted the conference, bringing doctor's from around the region to share their expertise in Oncology. Roche is a leading healthcare company based in Switzerland with a history of more than 100 years in the discovery, development, production and marketing of cost-effective prescription drugs of high quality. As a world leader in oncology, Roche continues to test and research new products such as Avastin®, a protein that is believed to play an important role in tumor angiogenesis. www.ameinfo.com /33542.html   (1074 words)

DOJ/Antitrust - Press Release Hoffmann-La Roche, BASF, and Sommer are cooperating with the investigation. Hoffmann-La Roche Ltd today agreed to plead guilty and pay a record $500 million criminal fine for leading a worldwide conspiracy to raise and fix prices and allocate market shares for certain vitamins sold in the United States and elsewhere, the Department of Justice announced. According to the charges, Hoffmann-La Roche and BASF agreed with the world's other major vitamin manufacturers to suppress and eliminate competition in the U.S. and elsewhere. www.usdoj.gov /atr/public/press_releases/1999/2450.htm   (1045 words)

Newsbytes News Network: Partners with Hoffmann-La Roche on Obesity Target - Companies to Collaborate on Continued Research of Melanocortin-4 Hoffmann-La Roche Inc. is a leading research-intensive pharmaceutical company that discovers, develops, manufactures and markets numerous important prescription drugs that improve, prolong and save the lives of patients with serious illnesses. "Our relationship with Hoffmann-La Roche represents a significant accomplishment and a great opportunity for Pharmacopeia," said Joseph A. Mollica, Ph.D., Chairman and CEO of Pharmacopeia. The company provides a wide range of medications in the United States through its marketing and sales subsidiary, Roche Laboratories, Inc. Headquartered in Nutley, NJ, both companies are members of the Basel, Switzerland-based Roche Group, a global leader in health care with principal businesses in pharmaceuticals, diagnostics, vitamins, and fragrances and flavours. www.findarticles.com /p/articles/mi_m0NEW/is_11_7/ai_57242466   (743 words)

Communities Protest Pricing of New Roche HCV Drug Pegasys Hoffmann-La Roche is unlikely to enjoy the level of open communications and trust it had recently achieved with the hepatitis and HIV communities. Many of us have worked for the last few years helping Roche and Trimeris ensure that the development of Fuzeon was responsive to community concerns and the needs of people with HIV. To Roche's credit, the company is offering 12 weeks of Pegasys free of charge to the first 15,000 patients who apply for the drug through their primary physicians. www.hivandhepatitis.com /hep_c/news/110102a.html   (1368 words)

Tat Drug: Parallel-Track Negotiations Status, ATN Issue 174, May 7 93 Hoffmann-La Roche refused, citing the dosage form as the primary rationale, and the need for a second efficacy trial to be underway as a secondary reason. But what Hoffmann-La Roche misses, despite numerous conversations and even a video presentation by people who have no options left, is this: It is not Hoffmann-La Roche's responsibility to protect people from a drug that may save them. Hoffmann-La Roche's acknowledgment of this fact, coupled with their refusal to take immediate steps to address it, is incomprehensible. www.hsph.harvard.edu /Organizations/healthnet/HIV/docs/atn/atn174d.htm   (1257 words)

Tat Inhibitor Trials Cancelled; Business Reasons Cited - AIDS Treatment News The Hoffmann-La Roche tat inhibitor is the only drug developed with its mode of action -- interfering with the protein produced by the tat gene of HIV, which is essential for viral replication. Dr. Oestreicher said that Hoffmann-La Roche is open to a wide range of potential business arrangements (to continue development of the potential tat drug), including co-development or licensing. Some people suspect that Hoffmann-La Roche may have stopped the trial because of doubts about whether the drug is in fact a tat inhibitor. www.aids.org /atn/a-127-01.html   (1666 words)

Princeton Review Internship Profile: Hoffmann-La Roche To meet the challenges of the dynamic and competitive pharmaceutical industry, Hoffmann-La Roche is planning for the future. Hoffmann-La Roche is mobilizing all of its talent, including interns. Roche discovers, develops, and markets prescription drugs in key therapeutic areas such as virology, infectious diseases, cardiology, oncology, transplantation and obesity. www.princetonreview.com /cte/profiles/internshipGenInfo.asp?internshipID=412   (231 words)

La Roche Thanks to the 16 dedicated employees from Hoffmann La-Roche for their generous donation of time and enthusiasm. For the second year in a row, employees from Hoffmann La-Roche rallied to the cause, and helped out at the Boys and Girls Club of Hawthorne, New Jersey. The United Way of Passaic County Volunteer Center reached out to Hoffmann La-Roche to see if they would be interested in a fun and rewarding community giveback program. www.bgchawthorne.org /LaRoche.shtml   (227 words)

Interroll - Interroll Hoffmann La Roche/D La Roche produces pharmaceuticals and distributes thousands of single packs and pieces per day to whole salers and hospitals. Hoffman La Roche set their sights on same-day despatch of all orders received by 2.30 pm. Using paperless technology, individual packs are picked from ergonomically optimised Pickflow storage lanes with incorporated roller and belt conveyors, while cartons are picked from a FIFO pallet flow storage system. www.interroll.com /?wm=c(282)sp(-1,6,203,261)   (110 words)

Background - Hoffmann La Roche The Roche Group is one of the world’s leading research-based healthcare groups active in the discovery, development and manufacture of pharmaceuticals and diagnostic systems. The group is also one of the world’s largest producers of vitamins and carotenoids and flavours and fragrances. cds.dl.ac.uk /cds/CIG/slides/roche/tsld004.htm   (42 words)

HOFFMANN-LA ROCHE LTD. v. FRANK W. HORNER LTD. I should add that counsel for the appellant was unable to distinguish in principle the case for royalty put forward in the present case from that which was put forward and rejected with respect to its chlordiazepoxide patent under the former s. (1) the cost of basic research conducted by Roche companies amounting alone to 11% of their world sales of drugs, (2) the costs of obtaining and maintaining medical acceptance of Roche drugs in Canada, and (3) an addition for return or profit on capital employed in research and in the provision of medical information. While an appeal lies from that decision, in order to succeed it is for the appellant to show that the Commissioner acted on a wrong principle or that, on the evidence, the decision was manifestly wrong: Parke, Davis & Co. v. www.cptech.org /ip/health/c/canada/horner-appeal.html   (9975 words)

Roche Products Australia ) is part of the International F. Hoffmann-La Roche Group worldwide that was founded in 1896 in © 1996-2005 F.Hoffmann-La Roche Ltd See our legal Statement Roche has grown from a small drug laboratory into one of the world's leading research-based Healthcare companies and is known for many innovative contributions to medicine. www.roche-australia.com   (71 words)

F. Hoffmann-La Roche Roche now the global leader in the flavours market. Nicholas was later integrated with the rest of the group's OTC business to form Roche Consumer Health. In 1999, Roche worldwide sales were approximately 27.6 billion Swiss francs (about $18.4 billion), with global pharmaceuticals sales accounting for about 60 percent of that total. www.informagen.com /Resource_Informagen/report.php?mrn=8306   (289 words)

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.